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Abstract
Cardiac dysfunction is frequently observed in patients 
with cirrhosis, and has long been linked to the direct 
toxic effect of alcohol. Cirrhotic cardiomyopathy (CCM) 
has recently been identiﬁed as an entity regardless of 
the cirrhosis etiology. Increased cardiac output due to 
hyperdynamic circulation is a pathophysiological hall-
mark of the disease. The underlying mechanisms in-
volved in pathogenesis of CCM are complex and involve 
various neurohumoral and cellular pathways, including 
the impaired β-receptor and calcium signaling, altered 
cardiomyocyte membrane physiology, elevated sympa-
thetic nervous tone and increased activity of vasodilato-
ry pathways predominantly through the actions of nitric 
oxide, carbon monoxide and endocannabinoids. The 
main clinical features of CCM include attenuated systol-
ic contractility in response to physiologic or pharmaco-
logic strain, diastolic dysfunction, electrical conductance 
abnormalities and chronotropic incompetence. Particu-
larly the diastolic dysfunction with impaired ventricular 
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relaxation and ventricular ﬁlling is a prominent feature of 
CCM. The underlying mechanism of diastolic dysfunction 
in cirrhosis is likely due to the increased myocardial wall 
stiffness caused by myocardial hypertrophy, fibrosis and 
subendothelial edema, subsequently resulting in high ﬁll-
ing pressures of the left ventricle and atrium. Currently, 
no specific treatment exists for CCM. The liver trans-
plantation is the only established effective therapy for 
patients with end-stage liver disease and associated 
cardiac failure. Liver transplantation has been shown to 
reverse systolic and diastolic dysfunction and the pro-
longed QT interval after transplantation. Here, we review 
the pathophysiological basis and clinical features of cir-
rhotic cardiomyopathy, and discuss currently available 
limited therapeutic options.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: Currently, little is known about the pathogen-
esis, diagnostic parameters and therapeutic principles 
of the cirrhotic cardiomyopathy. Increased cardiac 
output due to hyperdynamic circulation seems to be a 
pathophysiological hallmark of the disease. The main 
clinical features of cirrhotic cardiomyopathy include at-
tenuated systolic contractility in response to physiologic 
or pharmacologic strain, diastolic dysfunction, electrical 
conductance abnormalities and chronotropic incompe-
tence. Here, we review the pathophysiological basis 
and clinical features of cirrhotic cardiomyopathy, and 
discuss currently available therapeutic options.
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INTRODUCTION
Liver cirrhosis is associated with a wide range of  cardio-
vascular abnormalities. Cardiac dysfunction in cirrhotic 
patients was first described in patients with alcoholic 
cirrhosis. Thus, almost half  a century ago, Kowalski and 
Abelmann
[1]
 described a hyperdynamic circulation with 
high cardiac output, decreased arterial pressure and total 
peripheral resistance in patients with alcoholic cirrhosis. 
For many following years, cirrhosis-associated cardiac im-
pairment was therefore ascribed to the direct toxic effect 
of  alcohol.
The term cirrhotic cardiomyopathy (CCM) was first 
introduced more than 3 decades ago, and is defined as 
chronic cardiac dysfunction in cirrhotic patients in the 
absence of  known cardiac disease, irrespective of  the 
etiology of  cirrhosis
[2]
. Specific diagnostic criteria for 
CCM have recently been formulated by an international 
expert consensus committee (Figure 1). Besides increased 
cardiac output and low systolic blood pressure due to 
peripheral vasodilatation, frequent cardiac changes dur-
ing CCM include systolic and/or diastolic dysfunction, 
electrophysiological abnormalities and chronotropic in-
competence. Overt heart failure is not a typical feature of  
CCM. 
The exact prevalence of  CCM remains unknown, 
because the disease is generally inapparent at rest and be-
comes manifest under pharmacological or physical stress. 
Electrocardiographic changes, such as QT prolongation or 
diastolic dysfunction, are present in the majority of  patients 
with moderately or severely advanced liver failure (Child-
Pugh stage B or C)
[3]
. Generally, cardiomyopathy worsens 
with the progression of  the underlying liver failure. 
The following review is a brief  update on the patho-
genesis of  the disease, its clinical implication and man-
agement.
PATHOGENESIS OF CCM 
The underlying mechanisms involved in CCM are com-
plex and involve interplay of  multiple neurohumoral 
and cellular systems. Current thinking focuses on the 
increased cardiac output due to hyperdynamic circulation 
as the key pathogenetic event in CCM. Further studies 
demonstrated that cardiac contractile function is also 
adversely affected by cirrhosis, especially when cirrhotic 
patients are exposed to stress. 
CCM predominantly involves systemic multi-factorial 
cellular, neuronal and humoral signaling pathways. These 
include the impaired β-receptor and calcium signaling, 
altered cardiomyocyte membrane physiology, elevated 
sympathetic nervous tone and increased activity of  vaso-
dilatory pathways predominantly through the actions of  
nitric oxide (NO), carbon monoxide and endocannabi-
noids
[4]
. In addition, circulating plasma levels of  inﬂam-
matory and vasoactive molecules such as endothelins, 
glucagone, vasoactive intestinal peptide, tumor necrosis 
factor (TNF)-α, prostacycline and natriuretic peptide are 
usually accumulated in cirrhosis due to concomitant liver 
insufﬁciency and the presence of  portosystemic collater-
als, and, therefore, might be implied in the CCM patho-
genesis.
CELLULAR MECHANISMS
β-Receptor and calcium signaling
The β-adrenergic signaling is crucial in modulating car-
diac contractility and chronotropy. The possible role of  
decreased β-adrenergic receptor density in cirrhosis was 
ﬁrst reported by Gerbes et al
[5]
 more than 2 decades ago. 
Since then β-receptor-mediated pathways have exten-
sively been investigated in CCM. Indeed, the β-adrenergic 
receptor impairment with a decrease in chronotropic and 
inotropic responses may be an early sign of  CCM
[6]
. This 
is likely due to a reduction in both receptor density and 
function, and is found virtually in all patients with CCM. 
In an experimental cirrhosis model, decreased ex-
pression of  β-receptor density, G-protein subunits 
Gs and Gi2α with attenuated cAMP generation was re-
ported by several groups
[5,7,8]
. It was also demonstrated 
that β-adrenergic receptors were desensitized in vivo
[6]
. 
Interestingly, blunted muscarinic responsiveness in cir-
rhotic myocardium was also attributed to the impaired 
β-adrenergic pathway
[9]
.
Alterations in the ﬂuidity and biochemical properties 
of  the cellular membrane with increased cholesterol/
phospholipids ratio may cause the diminished β-receptor 
function too, and thus contribute to the pathogenesis 
of  cardiac contractility in cirrhosis
[10]
. Indeed, abnormal 
cell membrane ﬂuidity was detected in cardiac tissue
[11]
, 
erythrocytes
[12]
, kidneys
[13]
 and liver
[14]
 in cirrhosis. On the 
other hand, the impaired β-receptor signaling in CCM 
may also be associated with the increased sympathetic 
tone, a phenomenon frequently observed in end-stage 
liver disease. For example, Moreau et al
[15]
 showed that 
the central α-adrenergic agonist clonidine significantly 
reduced plasma norepinephrine levels and decreased 
hyperdynamic circulation in cirrhotic patients (Table 1). 
Consistently, β-receptor antagonists reduce cardiac out-
put in cirrhotic patients by lowering portal pressure and 
portal flow
[16]
. In this regard, non-selective β-blockers 
such as propranolol, nadolol and timolol are more effec-
tive than selective β1-blockers in reducing the hepatic 
venous pressure gradient
[17]
.
β-adrenergic stimulation or excitation-contraction 
coupling leads to the activation of  various calcium (Ca
2+
) 
related systems that are crucial for cardiac contraction. 
Therefore, alterations in Ca
2+
 homeostasis may explain 
the attenuated contractile responsiveness observed in the 
cirrhotic myocardium. Indeed, voltage-gated L-type Ca
2+
 
channel protein expression is significantly decreased in 
cardiomyocytes isolated from cirrhotic rats
[18]
. Moreover, 
Ca
2+
 entry as well as Ca
2+-
- release were diminished in 
cardiac myocytes in the biliary cirrhotic rat model.
Gassanov N et al . Cirrhotic cardiomyopathy, pathogenesis, hyperdynamic state
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VASOREGULATORY HUMORAL 
PATHWAYS
Nitric oxide
Among the vasodilators, most attention has been paid to 
NO as the key humoral factor implicated in pathogenesis 
of  hyperdynamic circulation. NO is synthesized in vas-
cular endothelium constitutively by NO synthase type 1 
(neuronal, nNOS) or type 3 (endothelial, eNOS); howev-
er, another isoform, the inducible NO synthase (inducible, 
iNOS) can be expressed upon stimulation with inﬂamma-
tory mediators. NO stimulates guanylate cyclase to pro-
duce cyclic guanosine monophosphate (cGMP), which 
phosphorylates protein kinase G to inhibit Ca
2+
 influx 
into the cytosol and, thus, eventually causing vasodila-
tion. NO exerts a variety of  effects on the cardiovascular 
system. Whereas NO synthesized by nNOS and eNOS 
exerts cardioprotective effects through improvement 
of  perfusion and inhibition of  apoptosis, iNOS-derived 
NO has a cardiotoxic effect through the suppression of  
muscle contractility and induction of  apoptosis
[19]
.
Plasma NO levels are consistently increased in cir-
rhotic patients in response to transient bacteremia and 
increased levels of  endotoxins and cytokines
[20]
. En-
hanced NO release has also been detected in splanchnic 
vasculature of  patients with cirrhosis
[21]
. In cardiac tissue, 
signiﬁcantly higher TNF-α, cGMP and iNOS levels were 
reported in cardiac homogenates obtained from cirrhot-
ic rats, indicating a possible cytokine - iNOS - cGMP 
mediated pathway in the pathogenesis of  CCM
[22]
. The 
same study analyzed further the NO-associated effects 
on cardiac contractility in isolated left ventricular papil-
lary muscles in response to treatment with the non-
speciﬁc NOS inhibitor nitro-L-arginine methyl ester (L-
NAME). The baseline isoproterenol-stimulated papillary 
muscle contractile force was shown to be lower than in 
the control groups. However, when the papillary muscles 
were pre-incubated with the L-NAME, contractile force 
increased signiﬁcantly in the cirrhotic rats. Similar results 
were previously reported by van Obbergh et al
[23]
 who 
described a signiﬁcantly increased ventricular contractil-
ity in cirrhotic rat hearts after treatment with the non-
specific NOS inhibitor, L-NMMA (N omega-mono-
methyl-L-arginine).
Together, enhanced NOS activity in cirrhotic myo-
cardium as well as the improvement of  myocardial con-
tractility after administration of  NOS inhibitors suggest a 
major participation of  NO in CCM.
Carbon monoxide
Carbon monoxide, which is mainly produced through 
the enzymatic actions of  heme oxygenase (HO), seems 
to have as similar biochemical properties as NO. High 
cGMP levels through activation of  guanylyl cyclase were 
also attributed to the actions of  carbon monoxide
[24]
.
Carbon monoxide acts as a physiological vasodilator 
in hepatic microcirculation
[25]
. In contrast, up-regulated 
inducible HO-1 mRNA expression was detected in the 
right ventricle in animal model of  congestive heart fail-
ure
[26]
. Increased carbon monoxide levels are frequently 
found in cirrhotic patients. Experimental evidence also 
suggests this substance may be implicated in CCM 
pathogenesis. This is largely based on the ﬁnding of  the 
elevated HO-1 mRNA and protein expression in left 
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Diagnosis of cirrhotic cardiomyopathy
Absence of known relevant 
cardiac disease
Systolic dysfunction
   Resting LVEF < 55%
   Decreased contractility under 
   physiological or pharmacological 
   stress
Diastolic dysfunction
   E/A ratio < 1.0
   Deceleration time > 200 ms
   Isovolumetric relaxation 
   time > 80 ms
Supportive criteria
   Chronotropic incompetence
   Electromechanical uncoupling
   Prolonged QTc interval
   Structural changes: 
   LA dilatation, LV hypertrophy
   Elevated BNP or troponin Ⅰ
Figure 1  Diagnostic criterion for cirrhotic cardiomyopathy, as deﬁned by the expert consensus committee at the World Congress of Gastroenterology in 
Montreal, Canada in 2005. LA: Left atria; LV: Left ventricle; EF: Ejection fraction; BNP: Brain natriuretic peptide.
Table 1  Hemodynamic and echocardiographic changes 
typically observed in cirrhotic cardiomyopathy
Increased cardiac output and blood volume
Decreased left ventricular afterload due to peripheral vasodilation 
Enhanced sympathetic nervous activity
Left ventricular hypertrophy 
Left atrial enlargement
Elevated left ventricular end-diastolic diameter
Impairment of diastolic function 
Evident systolic dysfunction only during stress
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reduced aerobic capacity and decreased maximal heart 
rate compared to controls
[36]
.
The cardiac dysfunction is associated with structural 
and contractile abnormalities. Thus, an enlargement in 
LV mass, LV end-diastolic and left atrial volumes was 
detected by magnetic resonance imaging
[37]
. Consistent 
with the radiologic ﬁndings, an echocardiographic evalu-
ation of  cardiac parameters in cirrhotic patients revealed 
a significant increase in LV end-diastolic diameter and 
a reduction in peak systolic velocity and systolic strain 
rate. Interestingly, similar structural changes have been 
observed in children with biliary atresia awaiting a liver 
transplantation
[38]
. 
In contrast to systolic impairment, diastolic dysfunc-
tion is a prominent feature of  CCM
[39,40]
. It describes an 
impairment of  ventricular relaxation with reduction of  
the early (E) and late (A) phase of  ventricular ﬁlling, as 
recorded by Doppler echocardiography. The underlying 
mechanism of  diastolic dysfunction in cirrhosis is likely 
due to the increased myocardial wall stiffness caused by 
myocardial hypertrophy, ﬁbrosis and sub-endothelial ede-
ma, and subsequently resulting in high ﬁlling pressures of  
the left ventricle and atrium
[4]
.
Several studies demonstrated the presence of  echo-
cardiographic parameters of  diastolic dysfunction, such 
as increased A and E wave velocities and deceleration 
times along with the decreased E/A ratio in cirrhotic pa-
tients, especially in those with ascites
[39,41]
. In patients with 
ascites, cardiac function can be additionally worsened 
due to the upward displacement of  the diaphragm and 
increasing intrathoracic pressure
[42]
. Subsequently, ascites 
can further diminish the right atrial and ventricular com-
pliance resulting in reduced ﬁlling and diastolic dysfunc-
tion of  the right heart
[43]
. Paracentesis has been shown 
to improve ventricular filling by the preload reduction 
and by the lowering of  the increased basal plasma renin 
activity, aldosterone, norepinephrine, and epinephrine. 
However, systolic function is generally not affected by 
the paracentesis
[39]
. 
Transjugular intrahepatic portosystemic shunts (TIPS) 
ameliorate - at least partially - the hyperdynamic state but 
can, conversely, aggravate heart function by increased 
cardiac preload that overstrains the left atrium and the 
right atrium and ventricle
[44]
. Indeed, a recent multicenter 
study investigating TIPS vs large volume paracentesis 
for treatment of  ascites, reported that 12% of  the TIPS 
group developed heart failure compared to none in the 
paracentesis group
[45]
.
In addition, reduced systolic and diastolic function 
may have prognostic implications as worsening cardiac 
failure may be a signiﬁcant factor in the development of  
renal vasoconstriction and renal dysfunction including 
hepatorenal syndrome
[46]
. 
Electrophysiologic abnormalities
Experimental and clinical evidence suggests that the 
altered ﬂuidity of  myocardial cell membrane and abnor-
malities in β-receptor signaling predominantly contribute 
ventricle of  cirrhotic rats
[27]
. Furthermore, treatment of  
cirrhotic heart with HO inhibitor, zinc protoporphyrin 
IX, restored the elevated cGMP levels
[27]
.
Endocannabinoids
Endogenous cannabinoids, such as anandamide and 
2-arachidonoylglycerol, are involved in a variety of  
pathological processes in chronic liver disease
[28]
. Endo-
cannabinoids exert a negative inotropic effect in humans 
and in animal models through their interaction with the 
inhibitory G-protein-coupled receptors, CB1 and CB2, 
leading to the inhibition of  adenylate cyclase activity and 
Ca
2+
 influx into the cytosol of  the cardiomyocytes
[29,30]
.
 
Enhanced expression of  anandamide and up-regulation 
of  the cannabinoid signaling pathway has been linked to 
the pathogenesis of  arterial hypotension in cirrhotic rat 
models
[28,31]
. Moreover, anandamide was identified as a 
selective splanchnic vasodilator in cirrhosis[32].
In a rat model of  carbon tetrachloride-induced cir-
rhosis anandamide tissue levels were markedly increased 
in both heart and liver
[33]
. Additionally, injection of  the 
CB1 antagonist acutely increased mean blood pressure 
and improved parameters of  cardiac systolic function in 
cirrhotic rats. In a rat model of  bile duct ligated cirrhosis, 
the blunted contractile response of  isolated left ventricu-
lar papillary muscle was restored after pre-incubation 
with a CB1 antagonist
[34]
, suggesting that CB 1-receptor 
antagonists might be useful to improve contractile func-
tion in CCM.
CLINICAL FEATURES
Most patients with stable liver disease have subtle myo-
cardial impairment that is not or less apparent on routine 
examination. However, with progression of  the liver dis-
ease or under physiological or pharmacological strain, the 
cardiac failure becomes manifest. 
Cardiac dysfunction resulting from cirrhosis includes 
impaired systolic or diastolic function, electrophysiologi-
cal abnormalities with a prolonged ventricular repolariza-
tion (QT interval) and chronotropic incompetence. Al-
though some diastolic alterations may precede the systolic 
disturbances, both forms of  dysfunction may develop 
simultaneously in cirrhotic patients.
Systolic/diastolic dysfunction
Cirrhotic patients exhibit usually normal to increased left 
ventricular (LV) ejection fraction at rest. Systolic dys-
function is generally manifested as a blunted increase in 
cardiac output and decreased contractility with exercise 
or pharmacological stress. For example, Grose et al
[35]
 
reported a submaximal increase in cardiac output follow-
ing exercise in both alcoholic and non-alcoholic cirrhotic 
patients compared with controls. Similarly, exercise in pa-
tients with cirrhosis caused an appropriate increase in LV 
end-diastolic pressure but without the expected increase 
in cardiac index or LV ejection fraction, indicating inad-
equate ventricular reserve
[36]
. During exercise, there was 
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to the electrophysiologic changes seen in cirrhotic pa-
tients. Thus, several transmembrane plasma membrane 
ion channels such as potassium (K
+
) and Ca
2+
 have been 
shown to be dysfunctional both in cirrhotic subjects and 
cirrhotic animals
[47,48]
. Interestingly, both ion channels 
seem to be predominantly involved in conduction abnor-
malities in cirrhotic patients
[49,50]
.
One of  the most common electrophysiologic changes 
reported in patients with cirrhosis irrespective of  its 
etiology is a QT interval prolongation detected by elec-
trocardiography. QT prolongation has been reported to 
occur in 37%-84% of  cirrhotic individuals with either 
alcoholic or nonalcoholic liver disease
[50]
. QT interval 
prolongation and variability can affect cardiac rhythm and 
cause serious rhythm disturbances including ventricular 
arrhythmias and sudden cardiac death. QT prolongation 
correlates directly with the severity of  the liver disease, 
as deﬁned by the Child-Pugh score
[50]
. Moreover, a direct 
relationship between plasma noradrenalin levels and the 
corrected QT interval was also reported suggesting that 
enhanced adrenergic stimulation of  myocardial cells may 
play a signiﬁcant role in abnormal repolarization
[50,51]
.
Chronotropic incompetence is another consistent 
ﬁnding in alcoholic as well as non-alcoholic cirrhosis, and 
refers to inability of  the sinus node to increase heart rate 
or contractility after appropriate exercise or pharmaco-
logical stimulation. Impaired β-receptor signaling and/or 
autonomic dysfunction are probably the mechanisms un-
derlying the blunted contractile and chronotropic respon-
siveness in CCM. Chronotropic incompetence has prog-
nostic relevance too, since it is associated with increased 
risk of  perioperative complications, especially in patients 
undergoing liver transplantation
[52,53]
.
TREATMENT STRATEGIES
Currently, no specific treatment exists for CCM. Given 
the pivotal role of  the cirrhosis itself  in the development 
of  circulatory abnormalities, efforts should be made to 
effectively treat the underlying cirrhotic disease.
In this respect, the liver transplantation is the only 
established effective treatment for patients with end-
stage liver disease and associated cardiac failure. Liver 
transplantation has been shown to reverse systolic and 
diastolic dysfunction and the prolonged QT interval after 
transplantation
[54,55]
. Additionally, there is a decrease in 
cardiac output, heart rate, pulmonary artery pressure, and 
an increase in arterial blood pressure and systemic vas-
cular resistance following liver transplantation
[56,57]
. The 
time course of  cardiac function recovery as well as fac-
tors determining reversibility of  the cardiac abnormalities 
after transplantation are not yet completely understood.  
Torregrosa et al
[54]
 reported significant improvement in 
diastolic and systolic function along with the reduction in 
myocardial mass between 6 and 12 mo after liver trans-
plantation. 
When heart failure becomes evident, treatment prin-
ciples should be as same as for non-cirrhotic heart failure, 
which include β-blockers, diuretics and preload/afterload 
reduction. Diuretics are highly effective in the manage-
ment of  CCM-associated fluid retention. While rapid 
symptomatic improvement and a decrease in volume 
overload are achieved with loop diuretics, especially for 
decompensated heart or liver failure, the long-term ther-
apy with these drugs is associated with several adverse ef-
fects, such as increased neurohormonal activation, wors-
ening renal function, and electrolyte disturbances
[58,59]
. 
β-blockers may reduce the hyperdynamic load and 
improve the prolonged QT interval, besides their effects 
on lowering the portal pressure and in the prevention of  
variceal bleeding. In patients with portal hypertension, 
β-blockers can be combined with nitrates, which are 
known to affect the coronary arteries and also have veno-
dilatory effects leading to preload reduction.
Aldosterone antagonists and ACE inhibitors have 
beneﬁcial effects in inhibition of  the renin-angiotensin-aldo-
sterone system overactivity, reduction of  LV dilatation and 
wall thickness as well as improvement of  diastolic func-
tion. However, both drug groups have not demonstrated 
long-term efficacy in the treatment of  CCM in clinical 
setting
[60,61]
. Moreover, ACE inhibitors should be applied 
with special caution because of  their potential to aggra-
vate the systemic vasodilation. Similarly, the use of  cardiac 
glycosides is currently not warranted, since short-acting 
cardiac glycosides did not improve cardiac contractility in 
patients with alcoholic cirrhosis and LV dysfunction
[62]
.
CONCLUSION
Cardiac abnormalities are common in patients with liver 
cirrhosis, regardless of  the etiology, and worsens prog-
nosis in these patients. They include increased cardiac 
output, low systolic blood pressure, systolic and/or dia-
stolic dysfunction, electrophysiological abnormalities and 
chronotropic incompetence. Overt cardiac failure is not 
a prominent feature of  cirrhosis. However, cardiac dys-
function becomes more apparent with progression of  the 
underlying liver disease.
Pathogenesis of  CCM is multifactorial with major 
involvement of  the impaired β-receptor signaling, altered 
cardiomyocyte membrane physiology, downregulation 
of  intracellular Ca
2+
 kinetics and increased activity of  va-
sodilatory pathways through the actions of  NO, carbon 
monoxide and endocannabinoids. 
Clinical management of  CCM remains uncertain 
because of  lack of  the clinical evidence and challenging 
diagnosis of  the disease. To date, there are no proven 
therapies apart from the liver transplantation, which was 
shown in some studies to reverse the associated cardiac 
abnormalities.
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